Beam Therapeutics Ownership | Who Owns Beam Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Beam Therapeutics Ownership Summary


Beam Therapeutics is owned by 115.22% institutional investors, 1.22% insiders. Farallon capital management is the largest institutional shareholder, holding 10.00% of BEAM shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 5.72% of its assets in Beam Therapeutics shares.

BEAM Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockBeam Therapeutics115.22%1.22%-16.44%
SectorHealthcare Stocks 279.19%10.58%-189.76%
IndustryBiotech Stocks 63.97%10.68%25.35%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Farallon capital management8.24M10.00%$204.33M
Blackrock7.63M9.34%$178.87M
Blackrock funding, inc. /de7.67M9.31%$190.26M
Vanguard group7.62M9.25%$189.03M
Ark investment management7.07M8.58%$175.29M
Arch venture management4.54M5.51%$112.60M
Nikko asset management americas3.96M4.80%$98.11M
Sumitomo mitsui trust3.96M4.80%$98.15B
Fmr3.32M4.03%$82.27M
State street3.08M3.73%$76.32M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Mwg management2.27M75.61%$56.22M
Arch venture management4.54M48.91%$112.60M
Redmile group1.53M2.64%$37.91M
Kynam capital management, lp1.76M2.57%$43.55M
Casdin capital1.25M2.06%$31.00M
Ark investment management7.07M1.46%$175.29M
Nikko asset management americas3.96M1.06%$98.11M
Farallon capital management8.24M1.04%$204.33M
Bellevue group1.52M0.72%$37.65M
Alphabet321.60K0.46%$7.98M

Top Buyers

HolderShares% AssetsChange
Ubs group1.82M0.01%1.63M
Blackrock7.63M0.00%928.75K
Ark investment management7.07M1.46%536.93K
Casdin capital1.25M2.06%475.00K
Kynam capital management, lp1.76M2.57%454.07K

Top Sellers

HolderShares% AssetsChange
Morgan stanley803.83K0.00%-3.32M
Darwin global management---2.12M
Fmr3.32M0.00%-894.22K
State street3.08M0.00%-852.18K
Logos global management lp---500.00K

New Positions

HolderShares% AssetsChangeValue
Woodline partners lp282.12K0.05%282.12K$7.00M
Marshall wace, llp55.00K0.00%55.00K$1.36M
Susquehanna fundamental investments52.73K0.02%52.73K$1.31M
Jacobs levy equity management41.08K0.00%41.08K$962.41K
Ubs oconnor30.00K0.00%30.00K$12.00K

Sold Out

HolderChange
Assetmark-8.00
Nelson, van denburg & campbell wealth management group-14.00
Northwestern mutual wealth management-24.00
Hollencrest capital management-26.00
Bessemer group-35.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 20252421.26%101,365,37024.41%1151.18%14316.26%46-28.13%
Dec 31, 20242373.95%81,473,3153.08%981.07%12017.65%65-1.52%
Sep 30, 20242251.81%78,990,3511.88%951.08%102-5.56%664.76%
Jun 30, 2024219-6.01%77,530,74310.73%941.15%107-21.90%6231.91%
Mar 31, 202423319.49%70,020,5921.73%901.20%13733.01%47-11.32%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
ARK Disruptive Innovation Full Composite5.75M5.72%970.29K
ARK Innovation ETF5.71M5.68%-8.56K
Vanguard Total Stock Mkt Idx Inv2.91M2.89%61.74K
Nikko AM ARK Disruptive Innovation A USD2.84M2.82%212.52K
Vanguard US Total Market Shares ETF2.33M2.34%2.59K
iShares Russell 2000 ETF2.35M2.33%1.15K
Vanguard Small Cap Index2.26M2.24%10.17K
ARK Genomic Revolution2.04M2.03%292.65K
ARK Genomic Revolution ETF1.97M1.95%-
BB Biotech AG Ord1.52M1.83%-

Recent Insider Transactions


DateNameRoleActivityValue
Apr 01, 2025Bellon Christine Chief Legal OfficerSell$104.12K
Apr 01, 2025Evans John M. CEOSell$562.68K
Apr 01, 2025Ciaramella Giuseppe PresidentSell$136.42K
Apr 01, 2025Cavanagh Bethany J SVP, Finance and TreasurerSell$55.33K
Apr 01, 2025Simon Amy Chief Medical OfficerSell$175.54K

Insider Transactions Trends


DateBuySell
2033 Q2--
2024 Q4-2
2024 Q3-3
2024 Q2-7
2024 Q1-7

BEAM Ownership FAQ


Who Owns Beam Therapeutics?

Beam Therapeutics shareholders are primarily institutional investors at 115.22%, followed by 1.22% insiders and -16.44% retail investors. The average institutional ownership in Beam Therapeutics's industry, Biotech Stocks , is 63.97%, which Beam Therapeutics exceeds.

Who owns the most shares of Beam Therapeutics?

Beam Therapeutics’s largest shareholders are Farallon capital management (8.24M shares, 10.00%), Blackrock (7.63M shares, 9.34%), and Blackrock funding, inc. /de (7.67M shares, 9.31%). Together, they hold 28.65% of Beam Therapeutics’s total shares outstanding.

Does Blackrock own Beam Therapeutics?

Yes, BlackRock owns 9.34% of Beam Therapeutics, totaling 7.63M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 178.87M$. In the last quarter, BlackRock increased its holdings by 928.75K shares, a 13.85% change.

Who is Beam Therapeutics’s biggest shareholder by percentage of total assets invested?

Mwg management is Beam Therapeutics’s biggest shareholder by percentage of total assets invested, with 75.61% of its assets in 2.27M Beam Therapeutics shares, valued at 56.22M$.

Who is the top mutual fund holder of Beam Therapeutics shares?

ARK Disruptive Innovation Full Composite is the top mutual fund holder of Beam Therapeutics shares, with 5.72% of its total shares outstanding invested in 5.75M Beam Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools